Overview |
bs-1282R-Cy5.5 |
ASPP1 Polyclonal Antibody, Cy5.5 Conjugated |
WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
Human |
Mouse, Rat, Dog, Cow, Horse, Chicken |
Specifications |
Cy5.5 |
Rabbit |
KLH conjugated synthetic peptide derived from human ASPP1 |
901-1090/1090 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target |
23368 |
Q96KQ4 |
Nucleus |
p53BP2 like; p85; PPP1R13B; apoptosis stimulating protein of P53 1; Apoptosis-stimulating of p53 protein 2; Tumor suppressor p53-binding protein 2; p53-binding protein 2; p53BP2; 53BP2; Bcl2-binding protein; Bbp; Renal carcinoma antigen NY-REN-51. |
iASPP (inhibitor of apoptosis stimulating protein of p53, RelA-associated inhibitor (RAI), NFKap B-interacting protein 1, protein phosphatase 1 regulatory subunit 13-like, PPP1R13L) is the third member of the ASPP family of proteins. Unlike ASPP1 and ASPP2, which interact with p53 and enhance its ability to induce apoptosis, iASPP inhibits apoptosis induced by p53 overexpression. iASPP has been identified in a yeast-two hybrid screen as an interacting protein of the p65 subunit of NFKap B (RelA),3 interacts with NFKap B in vivo, and acts as an efficient inhibitor of HIV-1 gene expression in which both NFKap b and Sp1 play major roles. iASPP expression is upregulated in human breast carcinomas expressing wild-type p53, and gene overexpression may play an important role in the leukemogenesis and/or progression of acute leukemia. Alternate Names: apoptosis stimulating protein of P53 1; Apoptosis-stimulating of p53 protein 2; Tumor suppressor p53-binding protein 2; p53-binding protein 2; p53BP2; 53BP2; Bcl2-binding protein; Bbp; Renal carcinoma antigen NY-REN-51. |
Application Dilution |
WB |
1:300-5000 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |